ADPT vs VTRS: fair value comparison
Adaptive Biotechnologies Corporation and Viatris Inc. · Updated 2026-10-19
ADPT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. VTRS is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, VTRS currently ranks higher by quality score.
| ADPT | VTRS | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $24.02 | $17.64 |
| 12-month range | $12.41–$29.84 | $10.11–$18.66 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #141 of 301 Healthcare | #140 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | High | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | High | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: ADPT fair value analysis · VTRS fair value analysis